GlassScriptPhysician profile
Reddiah B Mummaneni
NPI 1568516987
$12,908.19
in general payments reported to CMS, 2019-2025
58 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,405 · 2020: $1,994 · 2021: $2,103 · 2022: $2,187 · 2023: $2,212 · 2024: $1,209 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,914 · Travel and Lodging: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,913.61 |
| Travel and Lodging | $305.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,537.45 | 2019-2025 | |
| Abbvie INC. | $1,169.88 | 2021-2025 | |
| Inspire Medical Systems, INC. | $987.06 | 2022-2025 | Inspire |
| Biogen, INC. | $684.20 | 2019-2025 | Leqembi, Tysabri, Vumerity |
| Amgen INC. | $570.45 | 2020-2024 | Aimovig |
| Jazz Pharmaceuticals INC. | $555.63 | 2019-2024 | |
| Allergan, INC. | $553.45 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $474.04 | 2019-2023 | Ajovy |
| Supernus Pharmaceuticals, INC. | $436.97 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $427.49 | 2019-2024 | Nuplazid |
| Pfizer INC. | $421.26 | 2023-2025 | |
| Zyla Life Sciences, INC. | $370.07 | 2019-2020 | |
| Lundbeck LLC | $365.55 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $337.47 | 2019-2022 | |
| Genzyme Corporation | $285.06 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reddiah Mummaneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.